Poland's Selvita aims to raise $40 million in public offering

26 January 2018

Poland’s leading biotech firm Selvita (WSE: SLV) has confirmed its intention to conduct a secondary public offering.

The company is planning to offer up to 2.2 million newly issued shares and expects to raise PLN 140 million zlotys ($42 million) net. Funds raised will be used towards the execution of Selvita’s development strategy for the years 2017-2021, the main goal of which is to generate growth of the company’s value through self-financing of the early stages of discovery and development of its innovative R&D projects, as well as its commercialization at more advanced stages of development than it’s been done up to date.

According to the development strategy presented in August 2017, by the year 2021, Selvita is planning to achieve the following business goals:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK